Bio-path Holdings, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Bio-Path Holdings reports significant operational and financial challenges in its Q1 2026 Form 10-Q, including an operational pause, employee furloughs, and a continued going concern warning.
OTC.Pink
Bio-Path Holdings reported a significant accumulated deficit and $0 cash, leading to an operational pause and employee furloughs, while continuing to seek critical financing.
OTC.Pink
Bio-Path Holdings, a clinical-stage oncology and obesity drug developer, announced an operational pause and furloughed most employees due to critical capital constraints, raising substantial doubt about its ability to continue as a going concern.
OTC.Pink
10-Q: Bio-Path Holdings Reports Q1 2025 Results, Cites Ongoing Losses and Need for Additional Capital
Bio-Path Holdings reports a net loss of $2.9 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.
OTC.Pink
Bio-Path Holdings reported its Q3 2024 financial results, provided updates on its clinical trials, and addressed its ongoing efforts to regain compliance with Nasdaq listing requirements.
OTC.Pink
Bio-Path Holdings announced positive interim results from its Phase 2 clinical trial for prexigebersen in AML and secured $7.2 million in financing during the second quarter of 2024.
OTC.Pink
10-Q: Bio-Path Holdings Reports Q1 2024 Results, Cites Progress in Clinical Trials and Financial Updates
Bio-Path Holdings reported its Q1 2024 financial results, highlighting ongoing clinical trial progress and recent capital raising activities.